CJC-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
== Career == After completing his postdoctoral fellowship in France, in 1969, Watson returned the United States and held a position as an Assistant Professor in the Department of Pharmacology at Vanderbilt University, in Nashville Tennessee. Jack was promoted to Associate Professor with tenure in 1974. While at Vanderbilt, Watson published the first edition of Introduction to Mass Spectrometry: Biomedical, Environmental, and Forensic Applications in 1976. It was the first book to include journal titles as part of the cited literature. Harold G. (Harry) Walsh had just joined the ACS as director of the Short Course program. Walsh approached Watson and asked him to teach a course. Walsh also asked that Watson select someone from the mass spectrometry industry to co-teach the course. Watson had met O. David Sparkman, an American working for the French Gas Chromatography/Mass Spectrometry company, Riber, in Paris, a few months earlier. Watson asked Sparkman to contribute to the data systems part of the course. They taught the first session at the annual Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy in the Spring of 1978. They taught the course two more times that year at the annual ACS meetings and continued teaching into the first decade of the next millennium. In 1980 Watson accepted a joint appointment in the Departments of Biochemistry and Chemistry at Michigan State University, East Lansing Michigan. He also became the director (Principal Investigator) of the National Institutes of Health (NIH) P41 Regional Resource in Mass Spectrometry at MSU.
Contrail, also known as vapor trail – Long, thin artificial clouds that sometimes form behind aircraft Dilution (equation) – Chemistry concept Evaporation – Vaporization of a liquid from its surface Henry's law – Gas law regarding proportionality of dissolved gas Vaporizer (disambiguation)
The main isotopes of argon found on Earth are 40Ar (99.6%), 36Ar (0.34%), and 38Ar (0.06%). Naturally occurring 40K, with a half-life of 1.25×109 years, decays to stable 40Ar (11.2%) by electron capture or positron emission, and also to stable 40Ca (88.8%) by beta decay. These properties and ratios are used to determine the age of rocks by K–Ar dating. In Earth's atmosphere, 39Ar is made by cosmic ray activity, primarily by neutron capture of 40Ar followed by two-neutron emission. In the subsurface environment, it is also produced through neutron capture by 39K, followed by proton emission. 37Ar is created from the neutron capture by 40Ca followed by an alpha particle emission as a result of subsurface nuclear explosions. It has a half-life of 35 days. Between locations in the Solar System, the isotopic composition of argon varies greatly. Where the major source of argon is the decay of 40K in rocks, 40Ar will be the dominant isotope, as it is on Earth. Argon produced directly by stellar nucleosynthesis is dominated by the alpha-process nuclide 36Ar. Correspondingly, solar argon contains 84.6% 36Ar (according to solar wind measurements), and the ratio of the three isotopes 36Ar : 38Ar : 40Ar in the atmospheres of the outer planets is 8400 : 1600 : 1. This contrasts with the low abundance of primordial 36Ar in Earth's atmosphere, which is only 31.5 ppmv (= 9340 ppmv × 0.337%), comparable with that of neon (18.18 ppmv) on Earth and with interplanetary gasses, measured by probes.
Sources: en.wikipedia.org
=== Inductively coupled plasma === Selecting an internal standard in inductively coupled plasma spectroscopy can be difficult, because signals from the sample matrix can overlap with those belonging to the analyte. Yttrium is a common internal standard that is naturally absent in most samples. It has both a mid-range mass and emission lines that don't interfere with many analytes. The intensity of the yttrium signal is what the signal from the analyte gets compared to. In Inductively coupled plasma-mass spectrometry (ICP-MS), species with a similar mass to the analyte usually serve as good internal standards, though not in every case. Factors that also contribute to the effectiveness of an internal standard in ICP-MS include how close its ionization potential, change in enthalpy, and change in entropy are to the analyte. Inductively coupled plasma-optical emission spectroscopy (ICP-OES) internal standards can be selected by observing how the analyte and internal standard signals change with varying experimental conditions. This includes making adjustments to the sample matrix or instrumentation settings and evaluating whether the selected internal standard is reacting in the same way the analyte is.
=== Causes === Causes of insufficient vitamin D synthesis in the skin include insufficient exposure to UVB light from sunlight due to living in high latitudes (farther distance from the equator with resultant shorter daylight hours in winter). Serum concentration by the end of winter can be lower by one-third to half that at the end of summer. The prevalence of vitamin D deficiency increases with age due to a decrease in 7-dehydrocholesterol synthesis in the skin and a decline in kidney capacity to convert calcidiol to calcitriol, the latter seen to a greater degree in people with chronic kidney disease. Despite these age effects, elderly people can still synthesize sufficient calcitriol if enough skin is exposed to UVB light. Absent that, a dietary supplement is recommended. Other causes of insufficient synthesis are sunlight being blocked by air pollution, urban/indoor living, long-term hospitalizations and stays in extended care facilities, cultural or religious lifestyle choices that favor sun-blocking clothing, recommendations to use sun-blocking clothing or sunscreen to reduce risk of skin cancer, and lastly, the UV-B blocking nature of dark skin. Consumption of foods that naturally contain vitamin D is rarely sufficient to maintain a recommended serum concentration of 25(OH)D in the absence of the contribution of skin synthesis. Fractional contributions are roughly 20% diet and 80% sunlight.
== Awards == In 1980, she was the recipient of a Guggenheim Fellowship. Other honors include the Award for Distinguished Contributions to Psychology in the Public Interest of the American Psychological Association, the NYU Alumni Achievement Award, the Liberty Science Center Genius Award, the Distinguished Contributions of Basic Science to Applied Psychology award from the American Association of Applied and Preventive Psychology, the James McKeen Cattel Award, and the Gordon Allport Intergroup Relations Prize.
In Greece, the most popular iced coffee beverage is frappé, made of instant coffee (generally Nescafe), water, and optionally, sugar using either an electric mixer or a shaker to create foam. Ice cubes and, optionally, milk are added. Frappés became known outside of Greece as a result of the 2004 Summer Olympics in Athens. Frappés have become very popular in Cyprus and Romania. The second most popular iced coffee beverage in Greece is the freddo cappuccino which is topped with a cold milk foam known as afrógala (Greek: αφρόγαλα) and freddo espresso which is a double shot of espresso blended with ice cubes and served over ice.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.